Preclinical Oncology Models Market Size, Share & Trends Analysis Report By Product (Neuroblastoma, Prostate Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Skin Cancer, Others), By Application, By Model Host Species, By Region, And Segment Forecasts, 2025-2034

Report Id: 1093 Pages: 180 Last Updated: 03 November 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Preclinical Oncology Models Market Segmentation

Global Preclinical Oncology Models Market by Product

  • Patient-Derived Xenograft Models (PDX)
  • Cell Line Derived Xenograft Models
  • Syngeneic Models
  • Genetically engineered mouse models (GEMMs)
  • Orthotopic Models
  • Custom Xenograft and Syngeneic Model
  • Others 

Preclinical Oncology Models Market seg

Global Preclinical Oncology Models Market Based on Application

  • Neuroblastoma
  • Prostate Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Fibrosarcoma
  • Kidney Cancer
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Skin Cancer
  • Others

By Model Host Species

  • Mice
  • Rats
  • Hamsters / Rabbits
  • Others

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes

Global Preclinical Oncology Models Market Based on Region

Europe Preclinical Oncology Models Market Revenue Outlook

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Preclinical Oncology Models Market Revenue Outlook

  • U.S.
  • Canada

Asia Pacific Preclinical Oncology Models Market Revenue Outlook

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Preclinical Oncology Models Market Revenue Outlook

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Preclinical Oncology Models Market Revenue Outlook

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa
 
 
 

Chapter 1.    Methodology and Scope

1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global Preclinical Oncology Models Market Snapshot

Chapter 4.    Global Preclinical Oncology Models Market Variables, Trends & Scope

4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends
4.5.    Penetration & Growth Prospect Mapping
4.6.    Industry Analysis – Porter’s Five Forces Analysis
4.7.    Competitive Landscape & Market Share Analysis
4.8.    Technology Advancement in Preclinical Oncology Models
4.9.    COVID 19 Impact Analysis

Chapter 5.    Market Segmentation 1: Product Estimates & Trend Analysis

5.1.    Product Type & Market Share, 2024 & 2034
5.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

5.2.1.    Patient-Derived Xenograft Models (PDX)
5.2.2.    Cell Line Derived Xenograft Models
5.2.3.    Syngeneic Models
5.2.4.    Genetically engineered mouse models (GEMMs)
5.2.5.    Orthotopic Models
5.2.6.    Custom Xenograft and Syngeneic Model
5.2.7.    Others

Chapter 6.    Preclinical Oncology Models Market Segmentation 2: Application Estimates & Trend Analysis

6.1.    Application Analysis & Market Share, 2024 & 2034
6.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:

6.2.1.    Neuroblastoma
6.2.2.    Prostate Cancer
6.2.3.    Pancreatic Cancer
6.2.4.    Breast Cancer
6.2.5.    Colorectal Cancer

Chapter 7.    Preclinical Oncology Models Market Segmentation 3: By Model Host Species Estimates & Trend Analysis

7.1.    By Model Host Species Analysis & Market Share, 2024 & 2034
7.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Model Host Species:

7.2.1.    Mice 
7.2.2.    Rats 
7.2.3.    Rabbits

Chapter 8.    Preclinical Oncology Models Market Segmentation 4: By End User Estimates & Trend Analysis

8.1.    By End User Analysis & Market Share, 2024 & 2034
8.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End User:

8.2.1.    Pharmaceutical & Biotechnology Companies
8.2.2.    Pharmaceutical & Biotechnology Companies
8.2.3.    Pharmaceutical & Biotechnology Companies

Chapter 9.    Preclinical Oncology Models Market Segmentation 3: Regional Estimates & Trend Analysis

9.1.    North America

9.1.1.    North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by Product, 2021-2034
9.1.2.    North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.1.3.    North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.1.4.    North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by By Model Host Species, 2021-2034
9.1.5.    North America Preclinical Oncology Models Market revenue (US$ Million) estimates and forecasts by By End User, 2021-2034

9.1.5.1.    U.S.
9.1.5.2.    Canada

9.2.    Europe

9.2.1.    Europe Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.2.2.    Europe Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.2.3.    Europe Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
9.2.4.    Europe Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, 2021-2034
9.2.5.    Europe Preclinical Oncology Models Market revenue (US$ Million) by By End User, 2021-2034

9.2.5.1.    Germany
9.2.5.2.    Poland
9.2.5.3.    France
9.2.5.4.    Italy
9.2.5.5.    Spain
9.2.5.6.    UK
9.2.5.7.    Rest of Europe

9.3.    Asia Pacific

9.3.1.    Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.3.2.    Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.3.3.    Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by country, 2021-2034
9.3.4.    Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, 2021-2034
9.3.5.    Asia Pacific Preclinical Oncology Models Market revenue (US$ Million) by By End User, 2021-2034

9.3.5.1.    China
9.3.5.2.    India
9.3.5.3.    Japan
9.3.5.4.    Australia
9.3.5.5.    Rest of Asia Pacific

9.4.    Latin America

9.4.1.    Latin America Preclinical Oncology Models Market revenue (US$ Million) by Product, 2021-2034
9.4.2.    Latin America Preclinical Oncology Models Market revenue (US$ Million) by Application, 2021-2034
9.4.3.    Latin America Preclinical Oncology Models Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.4.4.    Latin America Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, (US$ Million) 2021-2034
9.4.5.    Latin America Preclinical Oncology Models Market revenue (US$ Million) by By End User, (US$ Million) 2021-2034

9.4.5.1.    Brazil
9.4.5.2.    Rest of Latin America

9.5.    MEA

9.5.1.    MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by Product, (US$ Million) 2021-2034
9.5.2.    MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by Application, (US$ Million) 2021-2034
9.5.3.    MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.5.4.    MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by By Model Host Species, (US$ Million) 2021-2034
9.5.5.    MEA revenue Preclinical Oncology Models Market revenue (US$ Million) by By End User, (US$ Million) 2021-2034

9.5.5.1.    South Africa
9.5.5.2.    Rest of MEA

Chapter 10.    Competitive Landscape

10.1.    Major Mergers and Acquisitions/Strategic Alliances
10.2.    Company Profiles

10.2.1.    Aragen Bioscience
10.2.2.    vivoPharm Pty. Ltd. (Cancer Genetics, Inc.)
10.2.3.    Bioduro
10.2.4.    Crown Bioscience Inc.
10.2.5.    Charles River
10.2.6.    Champion Oncology, Inc.
10.2.7.    GenOway S.A.
10.2.8.    Hera BioLabs
10.2.9.    Pharmatest Services
10.2.10.    Taconic Biosciences, Inc.
10.2.11.    The Jackson Laboratory

 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
8844
Security Code field cannot be blank!

Frequently Asked Questions

Global Preclinical Oncology Models Market is valued at USD 1335.7 Million in 2024 and is predicted to reach USD 3733.0 Million by 2034

Global Preclinical Oncology Models Market is expected to grow at a 10.9% CAGR during the forecast period for 2025-2034

Aragen Bioscience, vivoPharm Pty. Ltd. Bioduro, Crown Bioscience Inc., Charles River, Champion Oncology, Inc., Envigo, GenOway S.A., Hera BioLabs

By Model Host Species, By Product, By End User and By Application are the key segments of the Preclinical Oncology Models Market.

North America region is leading the Preclinical Oncology Models Market

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying